Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Daratumumab- and elotuzumab-based treatments for refractory POEMS syndrome -> 1 hematologic (8%), 7 VEGF (54%), 2 neurologic (15%) and 8 generalized clinical responses (62%); median time to next treatment was 11 months.”
Title: Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series
Authors: Tomoki Suichi, Sonoko Misawa, Kazumoto Shibuya, Marie Morooka, Moeko Ogushi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Emiko Sakaida, Satoshi Kuwabara
You can read the Full Article in Hematology.
More posts featuring Robert Orlowski.
